share_log

宜明昂科-B(01541.HK):IMM01(替达派西普)与替雷利珠单抗联用临床试验更新

IMM01 (Tirapazamine) with Trastuzumab Combination Therapy Clinical Trial Update for Yimingangco-B (01541.HK)

Gelonghui Finance ·  Jul 3 05:24

On July 3, Grong Hui announced that Yiming Angke-B (01541.HK) successfully administered the first dose to a patient in Phase III clinical trial for PD-1 inhibitor treatment with IMM01 (tirapazamine) and tabrelizumab for relapsed or refractory (R/R) classical Hodgkin's lymphoma (cHL) with recurrence or progression after treatment.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment